Ruolan Wang

Ms. Ruolan Wang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2023 in Viruses
Verified
Journal Article
Open access
PDF file
CHCassidy Henegar
Cassidy Henegar
ELEmilio Letang
Emilio Letang
RWRuolan Wang
Ruolan Wang
CHCharles Hicks
Charles Hicks
DFDainielle Fox
Dainielle Fox
VVVani Vannappagari
Vani Vannappagari
After a decade of dolutegravir (DTG) use in various antiretroviral therapy combinations and in diverse populations globally, it is critical to identify HIV strains with reduced drug susceptibility and monitor emergent resistance in people living with HIV who experience virologic failure while on DTG-based regimens. We searched the PubMed, Embase, and Cochrane databases to identify studies that reported DTG resistance-associated mutations (RAMs) emerging under selection pressure. Our review showed that RAMs conferring resistance to DTG were rare in 2-drug and 3-drug regimens used in real-world cohorts, corroborating data from clinical trials. The potency of DTG in maintaining virologic suppression was demonstrated, even in cases of pre-existing resistance to companion drugs in the regimen. Estimates of DTG RAMs depended on the population and certain risk factors, including monotherapy, baseline resistance or lack of genotypic testing, treatment history and prior virologic failure, and suboptimal treatment adherence. The RAMs detected after virologic failure, often in heavily treatment-experienced individuals with prior exposure to integrase strand transfer inhibitors, were G118R, E138K, G140A/C/R/S, Q148H/K/R, N155H, and R263K. Overall, these data highlight the durable effectiveness and high barrier to resistance of DTG as part of combination antiretroviral therapy in a wide variety of settings.

9 December 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
RWRuolan Wang
Ruolan Wang
MUMark Underwood
Mark Underwood
JLJosep M Llibre
Josep M Llibre
EMEnrique Bernal Morell
Enrique Bernal Morell
CBCynthia Brinson
Cynthia Brinson
MAMounir Ait-Khaled
Mounir Ait-Khaled
We compared proportions of participants with target detected, target not detected (TND), and elevated viral load (VL) and assessed baseline variables associated with week 144 inflammatory biomarker levels between dolutegravir-lamivudine (DTG/3TC) and tenofovir alafenamide–based regimens (TBRs) in the TANGO study (post hoc). TANGO is an open-label, multicenter, phase 3 study that randomized adults with VL <50 copies/mL to switch to once-daily fixed-dose DTG/3TC or continue TBR. At baseline and each study visit, the VL was measured. Elevated VL event frequencies were assessed, including “blips.” Interleukin 6, D-dimer, high-sensitivity C-reactive protein, soluble CD14, and soluble CD163 were measured at baseline and at week 144. Loge-transformed week 144 biomarker levels were compared between treatment groups using an analysis of covariance model adjusting for baseline variables. High, comparable proportions of participants had VL <40 copies/mL and TND at week 144 (DTG/3TC, 279 of 369 [76%]; TBR, 267 of 372 [72%], intention-to-treat exposed Snapshot analysis; adjusted difference, 3.9% [95% confidence interval, −2.5% to 10.2%]), with similar TND proportions at all postbaseline visits (123 of 369 [33%] vs 101 of 372 [27%], respectively). Similar proportions of DTG/3TC participants had ≥1 postbaseline VL ≥50 copies/mL (28 of 369 [8%] vs 42 of 372 [11%] for TBR), primarily blips (18 of 369 [5%] and 26 of 372 [7%], respectively). Week 144 inflammatory biomarker levels were low and comparable between groups and associated with multiple demographic and baseline characteristics, including baseline biomarker levels, indicating a multifactorial inflammatory response. Week 144 biomarker levels were low and generally comparable between treatment groups, reflecting similar, robust, and durable viral suppression observed using the stringent TND end point. Trial registration: ClinicalTrials.gov, NCT03446573.

29 August 2021 in Proceedings of the Institution of Mechanical Engineers, Part C: Journal of Mechanical Engineering Science
Verified
Journal Article
Closed access
PDF file
LWLiangwen Wang
Liangwen Wang
SZShizhao Zhang
Shizhao Zhang
CWCaidong Wang
Caidong Wang
RWRuolan Wang
Ruolan Wang
HZHuadong Zheng
Huadong Zheng
JZJihao Zhang
Jihao Zhang
In this paper, a cam-linkage mechanism with a swing follower with variable pivot has been studied. In this mechanism, the pivot of the swing follower is installed on a slider with an adjustable track direction, the follower performs a complex planar motion, and the motion range of the output angle can be adjusted according to the output requirements. In order to synthesize this mechanism, firstly, the relevant model is established and the basic structural parameters are optimized by considering the assembly conditions and the pressure angle under the limit position of the movement track of the follower mounting slider. Subsequently, the inverse method and the envelope theory are employed to derive the cam contour coordinates. Finally, the corresponding follower motion law is selected, the corresponding cam contour coordinates are calculated, and the entire cam contour curve is obtained using spline interpolation. An automatic design system for cam contours is developed. The processes are carried out through design examples and verified through motion simulations and prototype experiment. The present work can enrich the design theory of cam-linkage mechanisms.

11 June 2023 in Viruses
Verified
Journal Article
Open access
PDF file
RWRuolan Wang
Ruolan Wang
JWJonathan Wright
Jonathan Wright
PSParminder Saggu
Parminder Saggu
MAMounir Ait-Khaled
Mounir Ait-Khaled
RMRiya Moodley
Riya Moodley
MUMark Underwood
Mark Underwood
The TANGO study (ClinicalTrials.gov, NCT03446573) demonstrated that switching to dolutegravir/lamivudine (DTG/3TC) was non-inferior to continuing tenofovir alafenamide-based regimens (TBR) through week 144. Retrospective baseline proviral DNA genotypes were performed for 734 participants (post-hoc analysis) to assess the impact of archived, pre-existing drug resistance on 144-week virologic outcomes by last on-treatment viral load (VL) and Snapshot. A total of 320 (86%) participants on DTG/3TC and 318 (85%) on TBR had both proviral genotype data and ≥1 on-treatment post-baseline VL results and were defined as the proviral DNA resistance analysis population. Archived International AIDS Society–USA major nucleoside reverse transcriptase inhibitor, non-nucleoside reverse transcriptase inhibitor, protease inhibitor, and integrase strand transfer inhibitor resistance-associated mutations (RAMs) were observed in 42 (7%), 90 (14%), 42 (7%), and 11 (2%) participants, respectively, across both groups; 469 (74%) had no major RAMs at baseline. M184V/I (1%), K65N/R (99% of participants on DTG/3TC and 99% on TBR were virologically suppressed (last on-treatment VL <50 copies/mL) regardless of the presence of major RAMs. Results from the sensitivity analysis by Snapshot were consistent with the last available on-treatment VL. In TANGO, archived, pre-existing major RAMs did not impact virologic outcomes through week 144.

6 March 2024 in Viruses
Verified
Journal Article
Open access
PDF file
MUMark Underwood
Mark Underwood
RURimgaile Urbaityte
Rimgaile Urbaityte
RWRuolan Wang
Ruolan Wang
JHJoe Horton
Joe Horton
JOJames Oyee
James Oyee
JSJörg Sievers
Jörg Sievers
In GEMINI-1/-2, dolutegravir + lamivudine was non-inferior to dolutegravir + tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in achieving viral suppression (viral load [VL] < 50 copies/mL) in treatment-naive adults. Abbott’s RealTime HIV-1 assay provides quantitative VL (40–10,000,000 copies/mL) and qualitative target detected or target not detected (TND) for VL < 40 copies/mL. This post hoc analysis assessed very-low-level viremia and “blips” through Week 144. Proportions with VL < 40 copies/mL and TND are presented overall and by baseline VL and CD4+ cell count. “Blips” (single VL ≥ 50 to <200 copies/mL with adjacent values < 50 copies/mL) were assessed from Day 1 after VL suppression and from Weeks 48 through to 144. Proportions with TND increased through Week 48 and were similar between groups at all visits (Week 144: dolutegravir + lamivudine, 451/716 [63%]; dolutegravir + TDF/FTC, 465/717 [65%]). By observed analysis, TND rates were similar between groups across baseline subgroups. Through Week 144, proportions with ≥1 “blip” were generally comparable for dolutegravir + lamivudine vs. dolutegravir + TDF/FTC from Day 1 (15% vs. 20%) and from Week 48 (7% vs. 11%). Through 144 weeks, the proportions with TND or “blips” were similar between dolutegravir + lamivudine and the three-drug comparator, reinforcing the efficacy and durability of dolutegravir + lamivudine.